Yasmin and venous thromboembolism: New case reports

Clinical Hemorheology and Microcirculation

Volumn 42, Issue 1, 2009, Pages 65-69

  López, María ^a   Vayá, Amparo ^a   Martínez Triguero, M Luisa ^a   Contreras, M Teresa ^a   Todolí, José ^a   Ricart, Alicia ^b   Laiz, Begoña ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

Author keywords

Venous thromboembolism; Yasmin

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; DROSPIRENONE PLUS ETHINYLESTRADIOL; PLASMINOGEN ACTIVATOR; PROTHROMBIN; ANDROSTANE DERIVATIVE; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ACNE; ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; ECHOGRAPHY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; LUNG EMBOLISM; OBESITY; OVARY POLYCYSTIC DISEASE; PREGNANCY; PREMENSTRUAL SYNDROME; RISK FACTOR; SMOKING; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; CASE REPORT; CHEMICALLY INDUCED DISORDER; GENETIC PREDISPOSITION; GENETICS;

ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROTHROMBIN; RISK FACTORS; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 67651160746     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: 10.3233/CH-2009-1190     Document Type: Article

References (14)

1. T. Sheldon and G.P.S. Dutch, Warned against new contraceptive pill, BMJ 324 (2002), 869.
2. L.A. Heinemann and J. Dinger, Safety of a new oral contraceptive containing drospirenone, Drug Saf. 27 (2004), 1001-1118.
3. J. Dinger, L. Heinermann and D. Külh-Habich, The safety of a drospirenone-containing oral contraceptive: final results from the european active surveillance study on oral contraceptives based on 142, 475 women-years of observation, Contraception 75 (2007), 344-354.
4. G. Weiss, Risk of venous thromboembolism with third generation oral contraceptives: A review, Am. J. Obstet. Gynecol. 180 (1999), 295.
5. H. Jick, J. Kaye, C. Vasilakis-Scaramozza and S. Jick, Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis, BMJ 321 (2000), 1190-1195.
6. H.M. Pearce, D. Layton, L.V. Wilton and S.A. Shakir, Deep vein thrombosis and pulmonary embolism reported in the prescription event monitoring study of Yasmin, Br. J. Clin. Pharmacol. 60 (2005), 98-102.
7. K. van Grootheest and T. Vrieling, Thromboembolism associated with the new contraceptive Yasmin, BMJ 1 (2003), 257.
8. Y. Mira, C. Morata, A. Vayá, F. Ferrando, T. Contreras and J. Aznar, Is Yasmin as safe as other contraceptive pills?, Clin. Appl. Thromb. Hemost. 12 (2006), 378-379.
9. G. Ortí, Y. Mira and A. Vayá, Acute myocardial infarction associated with Yasmin oral contraceptive, Clin. Appl. Thromb. Hemost. 13 (2007), 336-337.
10. A. Girolami, F. Tezza, E. Allemand and B. Girolami, Arterial trombosis and drospirenone-containing pill (Yasmin). Is the pill to be absolutely avoided by women who smoke?, J. Thromb. Thrombol. 26 (2008), 163-164.
11. A. Vayá, Y. Mira, J. Mateo, C. Falcó, P. Villa, A. Estelles, D. Corella, J. Fontcuberta and J. Aznar, Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk, Thromb. Haemost. 89 (2003), 452-457.
12. T. Sagesaka, H. Juen and M. Hayashi, Influence of red blood cell concentration on the initiation time of blood coagulation: risk of thrombus formation in pregnant females with anemia, Clin. Hemorheol. Microcirc. 36 (2007), 155-161.
13. M. Abdollahi, M. Cushman and F.R. Rosendaal, Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use, Thromb. Haemost. 89 (2003), 493-498.
14. J. Aznar, Y. Mira, A. Vaya, F. Ferrando and P. Villa, Is family history sufficient to identify women with risk of vt before commencing the contraceptive pill?, Clin. Appl. Thromb. Hemost. 8 (2002), 139-141.